GlassScriptPhysician profile
Molly Parkton
NPI 1811614159
$1,148.11
in general payments reported to CMS, 2019-2025
21 companies · $863 in 2025
The $863 reported for 2025 was more than what 83% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $285 · 2025: $863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,148.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $259.65 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $121.32 | 2024-2025 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $106.16 | 2024-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $72.61 | 2025 | Trelegy Ellipta |
| Lilly USA, LLC | $65.64 | 2024-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.30 | 2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.33 | 2025 | Caplyta |
| Abbvie INC. | $56.58 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.12 | 2025 | |
| Sumitomo Pharma America, INC. | $50.59 | 2025 | Gemtesa |
| Exact Sciences Corporation | $32.52 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Dexcom, INC. | $29.12 | 2025 | Dexcom G6 Transmitter |
| Eisai INC. | $25.44 | 2024 | |
| Xeris Pharmaceuticals, INC. | $24.34 | 2025 | Gvoke Hypopen |
| Lundbeck LLC | $24.18 | 2025 | Rexulti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $20.83 | 2024 | Korlym |
| Otsuka America Pharmaceutical, INC. | $20.30 | 2025 | Rexulti |
| Boston Scientific Corporation | $19.57 | 2024 | General Dbs |
| Astellas Pharma US INC | $16.15 | 2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $14.80 | 2025 | |
| Esperion Therapeutics, INC. | $14.56 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Parkton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.